Venlafaxine's effect on resilience to stress is associated with a shift in the balance between glucose and fatty acid utilization

• Published in: Neuropsychopharmacology (New York, N.Y.) N.Y.), 2023-09, Vol.48 (10), p.1475-1483
• Main Authors: Brivio, Paola, Audano, Matteo, Gallo, Maria Teresa, Miceli, Eleonora, Gruca, Piotr, Lason, Magdalena, Litwa, Ewa, Fumagalli, Fabio, Papp, Mariusz, Mitro, Nico, Calabrese, Francesca
• Format: Article
• Language: English
• Subjects: Anhedonia - physiology; Animal models; Animals; Antidepressants; Antidepressive Agents - metabolism; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Central nervous system; Depression - drug therapy; Depression - metabolism; Disease Models, Animal; Energy metabolism; Fatty acids; Glucose - metabolism; Glycolysis; Hedonic response; Hippocampus; Humans; Mental depression; Mental disorders; Metabolism; Metabolites; Metabolomics; Phenotypes; Rats; Rats, Wistar; Stress, Psychological - metabolism; Therapeutic targets; Venlafaxine; Venlafaxine Hydrochloride - pharmacology
• ISSN: 0893-133X; 1740-634X; 1740-634X
• DOI: 10.1038/s41386-023-01633-0

Brain metabolism is a fundamental process involved in the proper development of the central nervous system and in the maintenance of the main higher functions in humans. As consequence, energy metabolism imbalance has been commonly associated to several mental disorders, including depression. Here, by employing a metabolomic approach, we aimed to establish if differences in energy metabolite concentration may underlie the vulnerability and resilience in an animal model of mood disorder named chronic mild stress (CMS) paradigm. In addition, we have investigated the possibility that modulation of metabolite concentration may represent a pharmacological target for depression by testing whether repeated treatment with the antidepressant venlafaxine may normalize the pathological phenotype by acting at metabolic level. The analyses were conducted in the ventral hippocampus (vHip) for its key role in the modulation of anhedonia, a core symptom of patients affected by depression. Interestingly, we showed that a shift from glycolysis to beta oxidation seems to be responsible for the vulnerability to chronic stress and that vHip metabolism contributes to the ability of the antidepressant venlafaxine to normalize the pathological phenotype, as shown by the reversal of the changes observed in specific metabolites. These findings may provide novel perspectives on metabolic changes that could serve as diagnostic markers and preventive strategies for the early detection and treatment of depression as well as for the identification of potential drug targets.